BIO-TECHNE Corp (TECH) stock
TECHNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 12, 2026Score 11/3040% above fair value
$72.84+0.04 (+0.05%)
Close on Nov 12, 2026Market cap $11.44BP/E 66.8Yield 0.44%
Bio-Techne revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Bio-Techne's revenue for the twelve months ending Sep 30, 2026 was $1.23B, up 0.9% year over year. For fiscal 2026 it was $1.22B, down 0.4% from the year before. Over ten years it grew 9.3% a year on average. The highest annual figure on record is $1.22B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $1.22B | -0.4% |
| FY2025 | Jun 30, 2025 | $1.22B | +5.2% |
| FY2024 | Jun 30, 2024 | $1.16B | +2.0% |
| FY2023 | Jun 30, 2023 | $1.14B | +2.8% |
| FY2022 | Jun 30, 2022 | $1.11B | +18.7% |
| FY2021 | Jun 30, 2021 | $931.03M | +26.0% |
| FY2020 | Jun 30, 2020 | $738.69M | +3.5% |
| FY2019 | Jun 30, 2019 | $714.01M | +11.0% |
| FY2018 | Jun 30, 2018 | $642.99M | +14.2% |
| FY2017 | Jun 30, 2017 | $563.00M | +12.8% |
| FY2016 | Jun 30, 2016 | $499.02M | +10.3% |
| FY2015 | Jun 30, 2015 | $452.25M | +26.4% |
| FY2014 | Jun 30, 2014 | $357.76M | +15.2% |
| FY2013 | Jun 30, 2013 | $310.58M | -1.3% |
| FY2012 | Jun 30, 2012 | $314.56M | +8.5% |
| FY2011 | Jun 30, 2011 | $289.96M | +7.8% |
| FY2010 | Jun 30, 2010 | $269.05M | +1.9% |
| FY2009 | Jun 30, 2009 | $263.96M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | $299.71M | +4.6% |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $321.19M | +1.3% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $311.42M | -1.5% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $295.88M | -0.4% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $286.56M | -1.0% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $316.96M | +3.5% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $316.18M | +4.2% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $297.03M | +9.0% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $289.46M | +4.5% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $306.10M | +1.6% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $303.43M | +3.2% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $272.60M | +0.4% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $276.94M | +2.7% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $301.32M | +4.5% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $294.15M | +1.3% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $271.58M | +0.9% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $269.66M | +4.6% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $288.23M | +11.3% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $290.38M | +19.2% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $269.28M | +20.1% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $257.72M | +26.2% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $259.03M | +47.3% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $243.55M | +25.1% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $224.25M | +21.3% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $204.20M | +11.4% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $175.83M | -8.3% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $194.68M | +5.3% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $184.93M | +6.0% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $183.24M | +12.4% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $191.66M | +6.3% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $184.86M | +12.7% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $174.51M | +13.2% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $162.97M | +12.7% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $180.25M | +15.1% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $163.97M | +13.8% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $154.15M | +17.0% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $144.61M | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $156.58M | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $144.04M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $131.81M | – |
See a number that looks wrong?